Table III.
Association between cirAE with overall survival using a multivariate time-varying Cox proportional hazards model
| Characteristic | Hazard ratio | 95% CI | P value |
|---|---|---|---|
| CirAE | 0.87 | 0.79, 0.98 | .027 |
| Sex | |||
| Female | Ref | Ref | |
| Male | 1.04 | 0.95, 1.13 | .4 |
| Age at ICI initiation | 1.00 | 0.99, 1.00 | .4 |
| Charlson Comorbidity Index | 1.09 | 1.07, 1.11 | <.001 |
| Race/ethnicity | |||
| White | Ref | Ref | |
| Asian | 1.08 | 0.86, 1.36 | .5 |
| Black | 0.90 | 0.69, 1.18 | .4 |
| Hispanic | 1.02 | 0.60, 1.74 | >.9 |
| Other/unknown | 0.84 | 0.62, 1.14 | .3 |
| Cancer type | |||
| Thoracic | Ref | Ref | |
| Melanoma | 0.44 | 0.38, 0.51 | <.001 |
| Gastrointestinal | 1.32 | 1.15, 1.51 | <.001 |
| Genitourinary | 0.79 | 0.68, 0.92 | .002 |
| Other* | 0.94 | 0.84, 1.05 | .3 |
| ICI type | |||
| CTLA-4 | Ref | Ref | |
| Combination therapy | 1.22 | 0.88, 1.69 | .2 |
| PD-1 | 0.94 | 0.69, 1.27 | .7 |
| PD-L1 | 0.77 | 0.55, 1.09 | .12 |
| Year of ICI initiation | 1.05 | 1.01, 1.09 | .014 |
CTLA-4, Cytotoxic T-lymphocyte protein 4; ICI, immune checkpoint inhibitor; PD-1, programmed cell death protein 1; Ref, reference group.
*
Other includes: brain/nervous system, breast, gynecologic, head and neck, hematologic, non-melanoma skin cancer, and sarcoma.